1461048368-aba127ec-e3f2-4059-a0ab-8cf07bc34ec3

1. A composition of crystalline N-5 (aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles of the following formula
having a purity of >99%,
wherein said particles in the composition have a particle size range from 1 to 500 \u03bcm, a particle size distribution which is defined by d(0.1) from 2 to 100 \u03bcm, d(0.5) from 30 to 210 \u03bcm and d(0.9) from 70 to 400 \u03bcm and a specific surface area of less than 1.0 m2g.
2. The composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles according to claim 1, wherein the N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles have a particle size range from 2 \u03bcm to 400 \u03bcm.
3. The composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles according to claim 1, wherein the particles have a particle size distribution which is defined by d(0.1) from 10 to 75 \u03bcm, d(0.5) from 100 to 175 \u03bcm, d(0.9) from 200 to 350 \u03bcm.
4. The composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles according to claim 1, wherein the particles have a specific surface area of less than 0.3 m2g.
5. A combination of the composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles according to claim 1 and acetylsalicylic acid, trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir, penciclovir, valaciclovir, famciclovir andor valganciclovir.
6-7. (canceled)
8. A pharmaceutical composition comprising the composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)phenylacetamide mono methanesulfonic acid monohydrate particles as defined in claim 1 and at least one pharmaceutically acceptable carrier, excipient, solvent andor diluent.
9. The pharmaceutical composition according to claim 8, wherein the composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles have a particle size range from 2 \u03bcm to 400 \u03bcm.
10. The pharmaceutical composition according to claim 8, wherein the composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles have a particle size distribution which is defined by d(0.1) from 10 to 75 \u03bcm, d(0.5) from 100 to 175 \u03bcm, d(0.9) from 200 to 350 \u03bcm.
11. The pharmaceutical composition according to claim 8, wherein the composition of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate particles have a specific surface area of less than 0.3 m2g.
12. A combination of the pharmaceutical composition according to claim 8 and acetylsalicylic acid, trifluridine, idoxuridine, foscarnet, cidofovir, ganciclovir, aciclovir, penciclovir, valaciclovir, famciclovir andor valganciclovir.
13-15. (canceled)
16. The pharmaceutical composition according to claim 8, which is effective to achieve an absolute bioavailability of 70%\xb130% of the free base of N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide, when administered in said composition containing at least 25 mg as free base equivalent of the crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate.
17. The pharmaceutical composition according to claim 8, which is effective to achieve a mean maximum blood plasma concentration (mean Cmax) of the free base of N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide in a subject of at least one of
a) 608\xb1184 ngml for a 40 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered;
b) 1306\xb1125 ngml for a 80 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered;
c) 2613\xb11341 ngml for a 160 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered;
d) 3600\xb1752 ngml for a 240 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered;
e) 4648\xb11813 ngml for a 320 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered;
f) 6926\xb11656 ngml for a 400 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered;
g) 6921\xb12190 ngml for a 480 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a single oral dose administered.
18. The pharmaceutical composition according to claim 8, which is effective to achieve a mean maximum blood plasma concentration (mean Cmax) of the free base of N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide in a subject of at least one of
a) 608\xb1184 ngml for a 40 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC0-24 h of 10090\xb13114 ng-hml in a subject for a 40 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 72\xb13 h on average; said dosage being a single oral dose administered;
b) 1306\xb1125 ngml for a 80 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC0-24 h of 21940\xb12057 ng-hml in a subject for a 80 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 74\xb15 h on average; said dosage being a single oral dose administered;
c) 2613\xb11341 ngml for a 160 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to a achieve an AUC0-24 h of 40470\xb116700 ng-hml in a subject for a 160 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 63\xb16 h on average; said dosage being a single oral dose administered;
d) 3600\xb1752 ngml for a 240 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC0-24 h of 59610\xb112770 ng-hml in a subject for a 240 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 64\xb15 h on average; said dosage being a single oral dose administered;
e) 4648\xb11813 ngml for a 320 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC0-24 h of 76250\xb127630 ng-hml in a subject for a 320 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 57\xb13 h on average; said dosage being a single oral dose administered;
f) 6926\xb11656 ngml for a 400 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC0-24 h of 104800\xb125740 ng-hml in a subject for a 400 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 57\xb14 h on average; said dosage being a single oral dose administered;
g) 6921\xb12190 ngml for a 480 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC0-24 h of 112800\xb134260 ng-hml in a subject for a 480 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 53\xb14 h on average; said dosage being a single oral dose administered.
19. The pharmaceutical composition according to claim 8, which is effective to achieve a mean maximum blood plasma concentration at steady state (mean Cmax,ss) of the free base of N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide in a subject of at least one of
a) 1358\xb1167 ngml for a 25 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a steady state dose achieved after once daily single doses administered for 21 days;
b) 6358\xb11701 ngml for a 100 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a steady state dose achieved after once daily single doses administered for 21 days;
c) 9987\xb12608 ngml for a 200 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, said dosage being a steady state dose achieved after once daily single doses administered for 21 days.
20. The pharmaceutical composition according to claim 8, which is effective to achieve a mean maximum blood plasma concentration at steady state (mean Cmax,ss) of the free base of N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide in a subject of at least one of
a) 1358\xb1167 ngml for a 25 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC\u03c4,ss of 23430\xb13020 ng-hml in a subject for a 25 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 69\xb16 h on average, said dosage being a steady state dose achieved after once daily single doses administered for 21 days;
b) 6358\xb11701 ngml for a 100 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate andor effective to achieve an AUC\u03c4,ss of 108800\xb128610 ng-hml in a subject for a 100 mg dosage as free base equivalent of crystalline N-5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl-N-methyl-2-4-(2-pyridinyl)-phenylacetamide mono methanesulfonic acid monohydrate, and wherein t12z is 60\xb14 h on average, said dosage being a steady state dose achieved after once daily single doses administered for 21 days.
21. The pharmaceutical composition of claim 16, wherein said absolute bioavailability is achieved in a human.
22. The pharmaceutical composition of claim 17, wherein said mean Cmax and Cmax,ss are achieved in a human.
23. The pharmaceutical composition of the claim 18, wherein said AUC0-24 h and t12z are achieved in a human.
24. The pharmaceutical composition of claim 20, wherein said AUC\u03c4,ss and t12z are achieved in a human.
25-27. (canceled)

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for controlling the radiation dose for generating an x-ray image of a focus region of a lithotripter, comprising the steps of:
generating an x-ray exposure of a focus region of a lithotripter by passing x-rays through the focus region and through at least one component of the lithotripter, said component producing a first region in said x-ray exposure shadowed by said component;
evaluating only a second region in said x-ray exposure, outside of said first region, to obtain an evaluation result; and
controlling a radiation dose of said x-rays, for producing subsequent x-ray exposures, using said evaluation result.
2. A method as claimed in claim 1 wherein the step of evaluating only said second region comprises evaluating an integral brightness of said second region to produce said evaluation result.
3. A method as claimed in claim 1 wherein said focus region has an immediate environment surrounding said focus region, and wherein said second region encompasses said environment.
4. A method as claimed in claim 1 comprising the additional step of lightening said first region by digital image processing.
5. A method as claimed in claim 1 comprising emitting said x-rays from an x-ray source having a center axis, and wherein said lithotripter has a center axis for shockwaves coinciding with said center axis of said x-ray source, and comprising gating said x-rays with a radiation diaphragm, and employing an image region as said second region that is disposed in a center of x-rays gated by said diaphragm.
6. A method as claimed in claim 5 comprising employing an image region as said second region having a circular shape.
7. A method as claimed in claim 1 wherein said lithotripter has a center axis along which said lithotripter generates shockwaves, and comprising generating said x-rays from an x-ray source having a center axis disposed at a non-zero angle relative to said center axis of said lithotripter.
8. A method as claimed in claim 7 comprising employing two spatially separated sub-regions in said x-ray exposure as said second region, both of said sub-regions being disposed outside of said first region.
9. A method as claimed in claim 8 comprising evaluating said second region by differently weighting said two sub-regions by differently weighting said two sub-regions.
10. A lithotripsy apparatus comprising:
a lithotripter having a focus region at which focused shockwaves are generated by said lithotripter, said lithotripter having at least one lithotripter component;
an x-ray source that emits x-rays for generating an x-ray exposure of said focus region, said x-rays also passing through said lithotripter component and said lithotripter component producing a first region in said x-ray exposure that is shadowed by said lithotripter component; and
an evaluation and control unit for evaluating only a second region of said x-ray exposure, disposed outside of said first region, for obtaining an evaluation result, and for controlling a dose of said x-rays for producing subsequent images of said focus region dependent on said evaluation result.
11. An apparatus as claimed in claim 10 comprising a switch for selectively deactivating control of said dose dependent on said evaluation result.
12. An apparatus as claimed in claim 10 wherein said evaluation and control unit evaluates an integral brightness of said second region for producing said evaluation result.
13. An apparatus as claimed in claim 10 wherein said focus region has an environment immediately surrounding said focus region, and wherein said evaluation and control unit employs an image region, as said second region, comprising said environment.
14. An apparatus as claimed in claim 10 wherein said evaluation and control unit lightens said first region by digital image processing.
15. An apparatus as claimed in claim 10 wherein said x-ray source has a center axis and wherein said lithotripter has a center axis coinciding with the center axis of said x-ray source, and comprising a diaphragm disposed in a path of said x-rays for gating said x-rays, and wherein said evaluation and control unit employs an image region in said x-ray exposure as said second region that is disposed in a center of the x-rays gated by said diaphragm.
16. An apparatus as claimed in claim 15 wherein said evaluation and control unit employs an image region as said second region having a circular shape.
17. An apparatus as claimed in claim 10 wherein said x-ray source has a center axis and wherein said lithotripter has a center axis disposed at a non-zero axis relative to said center axis of said x-ray source.
18. An apparatus as claimed in claim 17 wherein said evaluation and control unit employs two spatially separated sub-regions in said x-ray exposure as said second region, said two sub-regions being disposed outside of said first region.
19. An apparatus as claimed in claim 18 wherein said evaluation and control unit differently weights said two sub-regions for producing said evaluation result.